[1] 胡水清,张玫,牛小羽,等. 非酒精性脂肪性肝病的药物治疗进展. 现代生物医学进展,2014,11:2176-2179. [2] 李春君,张秋梅,于德民,等. 2型糖尿病合并非酒精性脂肪肝的治疗. 药品评价,2011,8(7):34-37. [3] 齐婷,许樟荣. 2型糖尿病合并非酒精性脂肪性肝病的研究进展. 国际内分泌代谢杂志,2010,30(6):398-400. [4] Takeuchi Y,Ito H,Komatsu Y,et al. Non-alcoholic fatty liver disease is an independent predictor for macroangiopathy in Japanese type 2 diabetic patients:A cross-sectional study. Intern Med,2012,13:1667-1675. [5] Leite NC,Salles GF,Araujo AL,et a1. Prevalence and associated factors of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. Liver Int,2009,29:113-119. [6] Targher G,Bertolini L,Padovani R,et a1. Prevalence of non alcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care,2007,30:1212-1218. [7] 张秋梅,张喆,李金金. 初诊2型糖尿病患者脂肪肝患病率及相关因素分析. 天津医科大学学报,2007,23(2):229-231. [8] 中华医学会肝脏病学分会脂肪肝和酒精性肝病组. 非酒精性脂肪性肝病诊疗指南(2010年修订版). 中华肝脏病杂志,2010,18(3):163-166. [9] 高鑫. 提高对非酒精性脂肪肝病的认识,早期防治代谢紊乱. 中华内分泌代谢杂志,2010,24(7):529-530. [10] Comar KM,Sterling RK. Drug therapy for nonalcoholic fatty liver disease. Aliment Pharmacol Ther,2006,23:207-215. [11] 孙存序,郑宪玲,檀增桓,等. 多烯磷脂酰胆碱联合二甲双胍治疗2型糖尿病合并非酒精性脂肪性肝病的临床观察. 临床荟萃,2008,17:1272-1273. [12] Hattori Y,Suzuki K,Hattori S,et al. Metformin inhibits cytokine-induced nuclear factor kappa B activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension,2006,47:1183-1188. [13] 张秀梅,胡长军,崔兆辉,等. 2型糖尿病并发非酒精性脂肪性肝病发病机制的研究进展. 现代生物医学进展,2013,8(7):1389-1391. [14] Cusi K. Nonalcoholic fatty liver disease in type 2 diabetes mellitus. Curr Opin Endocrinol Diabet Obes,2009,16:141-149. [15] 蓝苑元,雷宁,张晓菲,等. 续断提取物对非酒精性脂肪肝小鼠调脂保肝作用及其有效部位研究. 中草药,2011,12:2497-2501. [16] Yokohama S,Yoneda M,Haneda M,et al. Herapeuticeicacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology,2004,40:1222-1225. [17] Sanyal AJ,Chalasani N,Kowdley KV,et a1. Pioglitazone, vitamin E,or placebo for nonalcoholic steatohepatitis. N Engl J Med,2010,362:1675-1685. [18] Merat S,Malekzadeh R,Sohrabi MR,et al. Probucol in the treatment of nonalcoholic steatohepatitis:an open-labeled study. J Clin Gastroenterol,2003,36: 266-268. [19] 刘忠鑫,陈东风. 多烯磷脂酰胆碱联合还原型谷胱甘肽治疗非酒精性脂肪性肝炎87例临床研究. 当代医学,2012,9:19-20. [20] 甘波. 多烯磷脂酰胆碱联合生活方式干预治疗非酒精性脂肪性肝炎临床观察. 中国社区医师,2015,5:14-15. [21] 查月芳,刘芳,李力,等. 2型糖尿病合并非酒精性脂肪肝的临床特征及相关因素分析. 河北医药,2010,11:1369-1371. |